ATE226958T1 - Behandlung von hematologischen störungen mit einem igf-1/igfbp-3 komplex - Google Patents

Behandlung von hematologischen störungen mit einem igf-1/igfbp-3 komplex

Info

Publication number: ATE226958T1
Authority: AT; Austria
Prior art keywords: igfbp; igf; complex; treatment; hematological disorders
Prior art date: 1993-09-20

Application number

AT94928166T

Other languages

English (en)

Inventor

Joseph A Carlino

Howard R Higley

Christopher A Maack

Original Assignee

Celtrix Pharma

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1993-09-20

Filing date

1994-09-20

Publication date

2002-11-15

1994-09-20 Application filed by Celtrix Pharma filed Critical Celtrix Pharma

2002-11-15 Application granted granted Critical

2002-11-15 Publication of ATE226958T1 publication Critical patent/ATE226958T1/de

Links

102000004374 Insulin-like growth factor binding protein 3 Human genes 0.000 title abstract 5
108090000965 Insulin-like growth factor binding protein 3 Proteins 0.000 title abstract 5
108090000723 Insulin-Like Growth Factor I Proteins 0.000 title abstract 4
102000004218 Insulin-Like Growth Factor I Human genes 0.000 title 1
230000002489 hematologic effect Effects 0.000 title 1
102000013275 Somatomedins Human genes 0.000 abstract 3
239000003814 drug Substances 0.000 abstract 2
238000004519 manufacturing process Methods 0.000 abstract 2
208000026278 immune system disease Diseases 0.000 abstract 1
230000001589 lymphoproliferative effect Effects 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Public Health (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Immunology (AREA)
Chemical Kinetics & Catalysis (AREA)
Zoology (AREA)
Gastroenterology & Hepatology (AREA)
Epidemiology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Marine Sciences & Fisheries (AREA)
Oncology (AREA)
Diabetes (AREA)
Molecular Biology (AREA)
Endocrinology (AREA)
Transplantation (AREA)
Communicable Diseases (AREA)
Hematology (AREA)
Dermatology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)

AT94928166T 1993-09-20 1994-09-20 Behandlung von hematologischen störungen mit einem igf-1/igfbp-3 komplex ATE226958T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US12441093A	1993-09-20	1993-09-20
PCT/US1994/010629 WO1995008567A1 (en)	1993-09-20	1994-09-20	Treatment of immunologic and hematologic disorders with igfbp alone or complexed with igf

Publications (1)

Publication Number	Publication Date
ATE226958T1 true ATE226958T1 (de)	2002-11-15

Family

ID=22414706

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
AT94928166T ATE226958T1 (de)	1993-09-20	1994-09-20	Behandlung von hematologischen störungen mit einem igf-1/igfbp-3 komplex
AT02002410T ATE297214T1 (de)	1993-09-20	1994-09-20	Behandlung von immunologischen und hematologischen störungen mit igfbp allein oder als komplex mit igf

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
AT02002410T ATE297214T1 (de)	1993-09-20	1994-09-20	Behandlung von immunologischen und hematologischen störungen mit igfbp allein oder als komplex mit igf

Country Status (9)

Country	Link
US (1)	US5527776A (de)
EP (2)	EP1238674B1 (de)
JP (1)	JPH09507832A (de)
AT (2)	ATE226958T1 (de)
AU (1)	AU688793B2 (de)
CA (1)	CA2172158A1 (de)
DE (2)	DE69434403T2 (de)
ES (1)	ES2241906T3 (de)
WO (1)	WO1995008567A1 (de)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5728676A (en) *	1994-09-08	1998-03-17	Ciba-Geigy Corporation	Use of insulin-like growth factors I and II for inhibition of inflammatory response
US5869602A (en) *	1995-03-17	1999-02-09	Novo Nordisk A/S	Peptide derivatives
US5741776A (en) *	1995-05-22	1998-04-21	Genentech, Inc.	Method of administration of IGF-I
US6514937B1 (en)	1997-02-25	2003-02-04	Celtrix Pharmaceuticals, Inc.	Method of treating psychological and metabolic disorders using IGF or IGF/IGFBP-3
US6025368A (en) *	1997-02-25	2000-02-15	Celtrix Pharmaceuticals, Inc.	Method for treating the symptoms of chronic stress-related disorders using IGF
US6015786A (en) *	1997-02-25	2000-01-18	Celtrix Pharmaceuticals, Inc.	Method for increasing sex steroid levels using IGF or IGF/IGFBP-3
US6436897B2 (en) *	1998-06-01	2002-08-20	Celtrix Pharmaceuticals, Inc.	Pharmaceutical formulations for IGF/IGFBP
US6417330B1 (en)	1998-06-01	2002-07-09	Celtrix Pharmaceuticals, Inc.	Insulin-like growth factor binding protein variants
EP1117425A2 (de) *	1998-10-02	2001-07-25	Celtrix Pharmaceuticals, Inc.	Verfahren zur behandlung von nichtthyroidstörungen
US7288516B1 (en)	1999-09-20	2007-10-30	Celtrix Pharmaceuticals, Inc.	Null IGF for the treatment of cancer
US6040292A (en) *	1999-06-04	2000-03-21	Celtrix Pharmaceuticals, Inc.	Methods for treating diabetes
EP1191941A4 (de) *	1999-06-21	2006-12-13	Murdoch Childrens Res Inst	Methode der prophylaxe und/oder behandlung von erkrankungen
US6468290B1 (en)	2000-06-05	2002-10-22	Scimed Life Systems, Inc.	Two-planar vena cava filter with self-centering capabilities
CA2422625A1 (en) *	2000-09-19	2002-03-28	Bioexpertise, Llc	Method for use of igf-binding protein for selective sensitization of target cells in vivo
US6841386B2 (en)	2001-04-10	2005-01-11	Viacell, Inc.	Modulation of primary stem cell differentiation using an insulin-like growth factor binding protein
US6887851B2 (en) *	2001-09-18	2005-05-03	Bioexpertise, Llc	IGF-binding protein-derived peptide
US6861406B2 (en) *	2001-09-18	2005-03-01	Bioexpertise, Llc	IGF-binding protein-derived peptide
US6914049B2 (en)	2001-09-18	2005-07-05	Bioexpertise, Llc	IGF-binding protein-derived peptide or small molecule
US20050148509A1 (en) *	2003-07-09	2005-07-07	The University Of Iowa Research Foundation	Binding proteins as chemotherapy
US7625390B2 (en)	2004-04-16	2009-12-01	Cook Incorporated	Removable vena cava filter
US10022212B2 (en)	2011-01-13	2018-07-17	Cook Medical Technologies Llc	Temporary venous filter with anti-coagulant delivery method

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IL71991A (en) *	1983-06-06	1994-05-30	Genentech Inc	Preparation of human FGI and FGE in their processed form through recombinant AND tranology in prokaryotes
US4876242A (en) *	1987-09-21	1989-10-24	Merck & Co., Inc.	Human insulin-like growth factor analoges with reduced binding to serum carrier proteins and their production in yeast
ATE116335T1 (de) *	1987-12-24	1995-01-15	Gropep Pty Ltd	Peptid-analoge vom insulinähnlichen wachstums- faktor 1 (igf-1) oder faktor 2 (igf-2).
GB8826451D0 (en) *	1988-11-11	1988-12-14	Sandoz Ltd	Improvements in/relating to organic compounds
EP0556344B1 (de) *	1991-01-08	2003-08-13	Chiron Corporation	Insulinartigen wachstumsfaktor bindendes protein
US5187151A (en) *	1991-02-12	1993-02-16	Genentech, Inc.	Use of binding protein with igf-i as an anabolic growth promoting agent
US5202119A (en) *	1991-06-28	1993-04-13	Genentech, Inc.	Method of stimulating immune response

1994
- 1994-09-20 DE DE69434403T patent/DE69434403T2/de not_active Expired - Fee Related
- 1994-09-20 AT AT94928166T patent/ATE226958T1/de not_active IP Right Cessation
- 1994-09-20 AT AT02002410T patent/ATE297214T1/de not_active IP Right Cessation
- 1994-09-20 DE DE69431631T patent/DE69431631T2/de not_active Expired - Fee Related
- 1994-09-20 WO PCT/US1994/010629 patent/WO1995008567A1/en not_active Ceased
- 1994-09-20 EP EP02002410A patent/EP1238674B1/de not_active Expired - Lifetime
- 1994-09-20 EP EP94928166A patent/EP0726911B1/de not_active Expired - Lifetime
- 1994-09-20 AU AU77314/94A patent/AU688793B2/en not_active Ceased
- 1994-09-20 JP JP7509885A patent/JPH09507832A/ja not_active Ceased
- 1994-09-20 ES ES02002410T patent/ES2241906T3/es not_active Expired - Lifetime
- 1994-09-20 CA CA002172158A patent/CA2172158A1/en not_active Abandoned
1995
- 1995-02-23 US US08/393,249 patent/US5527776A/en not_active Expired - Lifetime

Also Published As

Publication number	Publication date
CA2172158A1 (en)	1995-03-30
US5527776A (en)	1996-06-18
JPH09507832A (ja)	1997-08-12
EP1238674A2 (de)	2002-09-11
ES2241906T3 (es)	2005-11-01
DE69434403D1 (de)	2005-07-14
AU7731494A (en)	1995-04-10
EP1238674B1 (de)	2005-06-08
DE69431631D1 (de)	2002-12-05
WO1995008567A1 (en)	1995-03-30
EP0726911A1 (de)	1996-08-21
ATE297214T1 (de)	2005-06-15
DE69434403T2 (de)	2006-05-04
EP0726911B1 (de)	2002-10-30
EP1238674A3 (de)	2002-10-23
AU688793B2 (en)	1998-03-19
EP0726911A4 (de)	1997-02-26
DE69431631T2 (de)	2003-07-31

Legal Events

Date	Code	Title	Description
2003-04-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties

Publication	Publication Date	Title
DE69431631D1 (de)	2002-12-05	Behandlung von hematologischen störungen mit einem igf-1/igfbp-3 komplex
GR3007092T3 (de)	1993-07-30
GR3015490T3 (en)	1995-06-30	Composition and method for the treatment of osteoporosis in mammals.
GR3032844T3 (en)	2000-07-31	Prevention and treatment of peripheral neuropathy.
IE871739L (en)	1988-01-01	Osteoinductive factor.
ATA105892A (de)	1995-06-15	Nagellack zur behandlung von onychomykosis enthaltend terbinafine
EP0341302A4 (en)	1990-09-05	Methods for prevention and treatment of mucositis with granulocyte colony stimulating factor
DE3687099D1 (de)	1992-12-17	Verwendung von einem cartilago-induzierenden faktor (cif) zur herstellung eines arzneimittels zur behandlung von entzuendungen.
ZA89813B (en)	1989-09-27	Method for treating renal diseases
ZA911496B (en)	1991-12-24	Use of 3-guanidinopropionic acid in the treatment and prevention of metabolic disorders
EP0661990A4 (de)	1995-05-22	Verfahren zur systemischen behandlung katabolischer zustände und systemischer gewebeschädigung.
DE68917433D1 (de)	1994-09-15	Verfahren zur behandlung von asbest sowie asbestbehandlungsmittel.
ES2144527T3 (es)	2000-06-16	Metodo para el tratamiento de disfunciones en la reproduccion.
DE3872614D1 (de)	1992-08-13	Verfahren zur behandlung der unfruchtbarkeit und mittel zur verwendung dabei.
ATE143804T1 (de)	1996-10-15	Zusammensetzung zur behandlung von mastitis und metritis
DE3751510D1 (de)	1995-10-12	Düse zur Behandlung von Fäden.
DE69433687D1 (de)	2004-05-13	Die verwendung von wachstumshormon zur herstellung eines medikaments zur behandlung der ischämischen hirnschädigung und demenz
DE3768595D1 (de)	1991-04-18	Einrichtung zur kontrolle und behandlung von gegenstaenden.